<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814307</url>
  </required_header>
  <id_info>
    <org_study_id>A3921045</org_study_id>
    <nct_id>NCT00814307</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis</brief_title>
  <official_title>Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550
      when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to
      severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in
      improving signs and symptoms and physical function that were observed in the Phase 2
      Rheumatoid Arthritis studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 functional categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3, 0=least functional difficulty and 3=extreme functional difficulty.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participant With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (=&lt;) 3.2 implied low disease activity, greater than (&gt;) 3.2 to 5.1 implied moderate to high disease activity and less than (&lt;) 2.6=remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 2, Month 1 and 2</measure>
    <time_frame>Week 2, Month 1, 2</time_frame>
    <description>ACR20 response: &gt;= 20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 4, 5 and 6</measure>
    <time_frame>Month 4, 5, 6</time_frame>
    <description>ACR20 response: &gt;= 20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 2, Month 1, 2 and 3</measure>
    <time_frame>Week 2, Month 1, 2, 3</time_frame>
    <description>ACR50 response: greater than or equal to &gt;=50% improvement in tender joint count; &gt;=50% improvement in swollen joint count; and &gt;=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 4, 5 and 6</measure>
    <time_frame>Month 4, 5, 6</time_frame>
    <description>ACR50 response: greater than or equal to &gt;=50% improvement in tender joint count; &gt;=50% improvement in swollen joint count; and &gt;=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 2, Month 1, 2 and 3</measure>
    <time_frame>Week 2, Month 1, 2, 3</time_frame>
    <description>ACR70 response: &gt;=70% improvement in tender joint count; &gt;=70% improvement in swollen joint count; and &gt;=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 4, 5 and 6</measure>
    <time_frame>Month 4, 5, 6</time_frame>
    <description>ACR70 response: &gt;=70% improvement in tender joint count; &gt;=70% improvement in swollen joint count; and &gt;=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline and Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PtGA of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (=&lt;) 3.2 implied low disease activity, greater than (&gt;) 3.2 to 5.1 implied moderate to high disease activity and less than (&lt;) 2.6=remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Week 2, Month 1, 2 and 3</measure>
    <time_frame>Baseline, Week 2, Month 1, 2, 3</time_frame>
    <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (milligram per liter [mg/L]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 4, 5 and 6</measure>
    <time_frame>Month 4, 5, 6</time_frame>
    <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Week 2, Month 1, 2 and 3</measure>
    <time_frame>Baseline, Week 2, Month 1, 2, 3</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 functional categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3, 0=least functional difficulty and 3=extreme functional difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire Disability Index (HAQ-DI) at Month 4, 5 and 6</measure>
    <time_frame>Month 4, 5, 6</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 functional categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3, 0=least functional difficulty and 3=extreme functional difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3</measure>
    <time_frame>Baseline, Week 2, Month 1, 2, 3</time_frame>
    <description>Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (most severe pain), measurement on a scale corresponds to the magnitude of their pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Arthritis Pain at Month 4, 5 and 6</measure>
    <time_frame>Month 4, 5, 6</time_frame>
    <description>Participants assessed the severity of their arthritis pain using a 100 mm visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (most severe pain), measurement on a scale corresponds to the magnitude of their pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3</measure>
    <time_frame>Baseline, Week 2, Month 1, 2, 3</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment (PtGA) of Arthritis Pain at Month 4, 5 and 6</measure>
    <time_frame>Month 4, 5, 6</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3</measure>
    <time_frame>Baseline, Week 2, Month 1, 2, 3</time_frame>
    <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment (PGA) of Arthritis Pain at Month 4, 5 and 6</measure>
    <time_frame>Month 4, 5, 6</time_frame>
    <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short-Form Health Survey (SF-36) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more intensity of attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline and Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcome Study Sleep Scale (MOS-SS) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more intensity of attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Baseline and Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Baseline and Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor,non-medical practitioner,nursing home,hospital,surgery,emergency room(ER) treatment,diagnostic tests, over-night stay,home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status,willingness to work,work disability due to RA,sick leave,part time work,ability to perform chores,chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor,non-medical practitioner,nursing home,hospital,surgery,emergency room(ER) treatment,diagnostic tests, over-night stay,home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status,willingness to work,work disability due to RA,sick leave,part time work,ability to perform chores,chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days as Assessed Using RA-HCRU at Baseline and Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days as Assessed Using RA-HCRU at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hours Per Days as Assessed Using RA-HCRU at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline and Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Limitations Questionnaire (WLQ) Score at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to First Greater Than 1 Day Sequential Decrease in Pain From Baseline for Patient Assessment of Arthritis Pain</measure>
    <time_frame>2 weeks</time_frame>
    <description>Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (most severe pain), measurement on a scale corresponds to the magnitude of their pain.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to First Greater Than 1 Day Sequential Decrease in Pain From Baseline for Patient Global Assessment of Arthritis</measure>
    <time_frame>2 weeks</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">611</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Active 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sequence 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sequence 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>5mg CP-690,550 BID PO for 6 months</description>
    <arm_group_label>Active 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>10 mg CP-690,550 BID PO for 6 months</description>
    <arm_group_label>Active 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit</description>
    <arm_group_label>Placebo Sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit</description>
    <arm_group_label>Placebo Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has a diagnosis of RA based upon the American College of Rheumatology
             (ACR) 1987 Revised Criteria.

          -  The patient has active disease at both Screening and Baseline, as defined by both: ≥6
             joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the
             following 2 criteria at Screening: 1.ESR (Westergren method) &gt;28 mm in the local
             laboratory. 2. CRP &gt;7 mg/L in the central laboratory

          -  Patient had an inadequate response to at least one DMARD (traditional or biologic) due
             to lack of efficacy or toxicity.

          -  No evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis.

          -  Patient has washed out of all DMARDs other that antimalarials

        Exclusion Criteria:

          -  Blood dyscrasias including confirmed: 1. Hemoglobin &lt;9 g/dL or Hematocrit &lt;30%; 2.
             White blood cell count &lt;3.0 x 109/L; 3. Absolute neutrophil count &lt;1.2 x 109/L; 4.
             Platelet count &lt;100 x 109/L

          -  History of any other autoimmune rheumatic disease other than Sjogren's syndrome

          -  No malignancy or history of malignancy.

          -  History of infection requiring hospitalization, parenteral antimicrobial therapy, or
             as otherwise judged clinically significant by the investigator, within the 6 months
             prior to the first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zephyr Hills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Olean</city>
        <state>New York</state>
        <zip>14760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611-1124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-240</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05437-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1709</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>7510186</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>8360156</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Providencia</city>
        <state>Santiago, RM</state>
        <zip>7530206</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bucaramanga</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ceska Lipa</city>
        <zip>470 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hlucin</city>
        <zip>748 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santo Domingo</city>
        <zip>00000</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nuernberg</city>
        <zip>90429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Secunderabad</city>
        <state>Andra Pradesh</state>
        <zip>500 003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 079</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kota Kinabalu</city>
        <state>Sabah</state>
        <zip>88586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Petaling Jaya</city>
        <state>Selangor Darul Ehsan</state>
        <zip>46150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Putrajaya</city>
        <state>Wilayah Persekutuan</state>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California</state>
        <zip>22010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dasmarinas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bajada, Davao City</city>
        <state>Phlippines</state>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Piñas City</city>
        <zip>1742</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-256</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61178</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lviv</city>
        <zip>79011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Simferopol, Crimea</city>
        <zip>95017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Dominican Republic</country>
    <country>Germany</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921045&amp;StudyName=A%20Phase%203%20study%20comparing%202%20doses%20of%20CP-690%2C550%20vs.%20placebo%20for%20treatment%20of%20rheumatoid%20arthritis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2008</study_first_posted>
  <results_first_submitted>December 5, 2012</results_first_submitted>
  <results_first_submitted_qc>December 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 11, 2013</results_first_posted>
  <disposition_first_submitted>November 18, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>November 18, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 29, 2010</disposition_first_posted>
  <last_update_submitted>January 10, 2013</last_update_submitted>
  <last_update_submitted_qc>January 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antirheumatic Agents Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CP-690,550 5 mg</title>
          <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
        </group>
        <group group_id="P2">
          <title>CP-690,550 10 mg</title>
          <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
        </group>
        <group group_id="P3">
          <title>Placebo, Then CP-690,550 5 mg</title>
          <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
        </group>
        <group group_id="P4">
          <title>Placebo, Then CP-690,550 10 mg</title>
          <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="245"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="243"/>
                <participants group_id="P2" count="245"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="218"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CP-690,550 5 mg</title>
          <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
        </group>
        <group group_id="B2">
          <title>CP-690,550 10 mg</title>
          <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
        </group>
        <group group_id="B3">
          <title>Placebo, Then CP-690,550 5 mg</title>
          <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
        </group>
        <group group_id="B4">
          <title>Placebo, Then CP-690,550 10 mg</title>
          <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="243"/>
            <count group_id="B2" value="245"/>
            <count group_id="B3" value="61"/>
            <count group_id="B4" value="61"/>
            <count group_id="B5" value="610"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="11.5"/>
                    <measurement group_id="B2" value="52.4" spread="11.7"/>
                    <measurement group_id="B3" value="50.7" spread="12.8"/>
                    <measurement group_id="B4" value="48.8" spread="11.9"/>
                    <measurement group_id="B5" value="51.8" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3</title>
        <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
        <time_frame>Month 3</time_frame>
        <population>Full Analysis Set (FAS): all randomized participants who received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed)=participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3</title>
          <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
          <population>Full Analysis Set (FAS): all randomized participants who received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed)=participants evaluable for this measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.75"/>
                    <measurement group_id="O2" value="65.70"/>
                    <measurement group_id="O3" value="26.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Normal approximation for the difference in binomial proportions was used to test the superiority of each dose of CP-690,550 to placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A step-down procedure was used to control for multiple comparisons. In order for the comparison to 5 mg to be statistically significant, the comparison to 10 mg had to be statistically significant.</p_value_desc>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>39.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.12</ci_lower_limit>
            <ci_upper_limit>48.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Normal approximation for the difference in binomial proportions was used to test the superiority of each dose of CP-690,550 to placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A step-down procedure was used to control for multiple comparisons. In order for the comparison to 5 mg to be statistically significant, the comparison to 10 mg had to be statistically significant.</p_value_desc>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>33.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.04</ci_lower_limit>
            <ci_upper_limit>43.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 functional categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3, 0=least functional difficulty and 3=extreme functional difficulty.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n' signifies those participants who were evaluable at given time points for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 functional categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3, 0=least functional difficulty and 3=extreme functional difficulty.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n' signifies those participants who were evaluable at given time points for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=240,241,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.66"/>
                    <measurement group_id="O2" value="1.50" spread="0.64"/>
                    <measurement group_id="O3" value="1.53" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3 (n=237,227,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.66"/>
                    <measurement group_id="O2" value="-0.54" spread="0.60"/>
                    <measurement group_id="O3" value="-0.18" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>p-value was calculated using linear mixed effect model. The fixed effects of treatment, visit, and treatment-by-visit interaction were included, along with participant as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>A step-down procedure was used to control for multiple comparisons. For comparison of 10 mg to placebo to be statistically significant in this measure, comparison of 10 mg to placebo in ACR20 had to be significant.</p_value_desc>
            <method>Linear mixed effect model</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>p-value was calculated using linear mixed effect model. The fixed effects of treatment, visit, and treatment-by-visit interaction were included, along with participant as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A step-down procedure was used to control for multiple comparisons. For comparison of 5 mg to placebo to be statistically significant, comparison of 10 mg to placebo and comparison of 5 mg to placebo in ACR20 had to be statistically significant.</p_value_desc>
            <method>Linear mixed effect model</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participant With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 3</title>
        <description>DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (=&lt;) 3.2 implied low disease activity, greater than (&gt;) 3.2 to 5.1 implied moderate to high disease activity and less than (&lt;) 2.6=remission.</description>
        <time_frame>Month 3</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participant With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 3</title>
          <description>DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (=&lt;) 3.2 implied low disease activity, greater than (&gt;) 3.2 to 5.1 implied moderate to high disease activity and less than (&lt;) 2.6=remission.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.11"/>
                    <measurement group_id="O2" value="10.05"/>
                    <measurement group_id="O3" value="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Normal approximation for the difference in binomial proportions was used to test the superiority of each dose of CP-690550 to placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0728</p_value>
            <p_value_desc>A step-down procedure was used to control for multiple comparisons. For comparison of 10 mg to placebo to be statistically significant in this measure, comparison of 10 mg to placebo in HAQ-DI had to be significant.</p_value_desc>
            <method>Normal Approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>5.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>10.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Normal approximation for the difference in binomial proportions was used to test the superiority of each dose of CP-690550 to placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6193</p_value>
            <p_value_desc>A step-down procedure was used to control for multiple comparisons. For comparison of 5 mg to placebo to be statistically significant, comparison of 10 mg to placebo and comparison of 5 mg to placebo in HAQ-DI had to be statistically significant.</p_value_desc>
            <method>Normal Approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.85</ci_lower_limit>
            <ci_upper_limit>6.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 2, Month 1 and 2</title>
        <description>ACR20 response: &gt;= 20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Week 2, Month 1, 2</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 2, Month 1 and 2</title>
          <description>ACR20 response: &gt;= 20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.58"/>
                    <measurement group_id="O2" value="39.17"/>
                    <measurement group_id="O3" value="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.47"/>
                    <measurement group_id="O2" value="52.07"/>
                    <measurement group_id="O3" value="21.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.85"/>
                    <measurement group_id="O2" value="60.74"/>
                    <measurement group_id="O3" value="25.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 4, 5 and 6</title>
        <description>ACR20 response: &gt;= 20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Month 4, 5, 6</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 4, 5 and 6</title>
          <description>ACR20 response: &gt;= 20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.29"/>
                    <measurement group_id="O2" value="69.01"/>
                    <measurement group_id="O3" value="51.67"/>
                    <measurement group_id="O4" value="61.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.46"/>
                    <measurement group_id="O2" value="69.83"/>
                    <measurement group_id="O3" value="61.67"/>
                    <measurement group_id="O4" value="63.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.29"/>
                    <measurement group_id="O2" value="71.07"/>
                    <measurement group_id="O3" value="58.33"/>
                    <measurement group_id="O4" value="56.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 2, Month 1, 2 and 3</title>
        <description>ACR50 response: greater than or equal to &gt;=50% improvement in tender joint count; &gt;=50% improvement in swollen joint count; and &gt;=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.</description>
        <time_frame>Week 2, Month 1, 2, 3</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 2, Month 1, 2 and 3</title>
          <description>ACR50 response: greater than or equal to &gt;=50% improvement in tender joint count; &gt;=50% improvement in swollen joint count; and &gt;=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83"/>
                    <measurement group_id="O2" value="12.92"/>
                    <measurement group_id="O3" value="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.43"/>
                    <measurement group_id="O2" value="23.97"/>
                    <measurement group_id="O3" value="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.14"/>
                    <measurement group_id="O2" value="33.88"/>
                    <measurement group_id="O3" value="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.12"/>
                    <measurement group_id="O2" value="36.78"/>
                    <measurement group_id="O3" value="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 4, 5 and 6</title>
        <description>ACR50 response: greater than or equal to &gt;=50% improvement in tender joint count; &gt;=50% improvement in swollen joint count; and &gt;=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.</description>
        <time_frame>Month 4, 5, 6</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 4, 5 and 6</title>
          <description>ACR50 response: greater than or equal to &gt;=50% improvement in tender joint count; &gt;=50% improvement in swollen joint count; and &gt;=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.34"/>
                    <measurement group_id="O2" value="42.98"/>
                    <measurement group_id="O3" value="28.33"/>
                    <measurement group_id="O4" value="28.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.42"/>
                    <measurement group_id="O2" value="45.45"/>
                    <measurement group_id="O3" value="36.67"/>
                    <measurement group_id="O4" value="35.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.91"/>
                    <measurement group_id="O2" value="46.69"/>
                    <measurement group_id="O3" value="33.33"/>
                    <measurement group_id="O4" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 2, Month 1, 2 and 3</title>
        <description>ACR70 response: &gt;=70% improvement in tender joint count; &gt;=70% improvement in swollen joint count; and &gt;=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.</description>
        <time_frame>Week 2, Month 1, 2, 3</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 2, Month 1, 2 and 3</title>
          <description>ACR70 response: &gt;=70% improvement in tender joint count; &gt;=70% improvement in swollen joint count; and &gt;=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08"/>
                    <measurement group_id="O2" value="4.58"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98"/>
                    <measurement group_id="O2" value="9.09"/>
                    <measurement group_id="O3" value="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.96"/>
                    <measurement group_id="O2" value="19.01"/>
                    <measurement group_id="O3" value="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.35"/>
                    <measurement group_id="O2" value="20.25"/>
                    <measurement group_id="O3" value="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 4, 5 and 6</title>
        <description>ACR70 response: &gt;=70% improvement in tender joint count; &gt;=70% improvement in swollen joint count; and &gt;=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.</description>
        <time_frame>Month 4, 5, 6</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 4, 5 and 6</title>
          <description>ACR70 response: &gt;=70% improvement in tender joint count; &gt;=70% improvement in swollen joint count; and &gt;=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.92"/>
                    <measurement group_id="O2" value="26.03"/>
                    <measurement group_id="O3" value="13.33"/>
                    <measurement group_id="O4" value="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.16"/>
                    <measurement group_id="O2" value="28.51"/>
                    <measurement group_id="O3" value="18.33"/>
                    <measurement group_id="O4" value="18.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.99"/>
                    <measurement group_id="O2" value="29.34"/>
                    <measurement group_id="O3" value="20.00"/>
                    <measurement group_id="O4" value="21.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline and Month 3</title>
        <description>DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PtGA of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. 'N' (number of participants analyzed)=participants evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline and Month 3</title>
          <description>DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PtGA of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>FAS population. 'N' (number of participants analyzed)=participants evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 236, 234, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.71" spread="0.93"/>
                    <measurement group_id="O2" value="6.70" spread="0.94"/>
                    <measurement group_id="O3" value="6.65" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 229, 219, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="1.37"/>
                    <measurement group_id="O2" value="4.55" spread="1.39"/>
                    <measurement group_id="O3" value="5.54" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 6</title>
        <description>DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (=&lt;) 3.2 implied low disease activity, greater than (&gt;) 3.2 to 5.1 implied moderate to high disease activity and less than (&lt;) 2.6=remission.</description>
        <time_frame>Month 6</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 6</title>
          <description>DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (=&lt;) 3.2 implied low disease activity, greater than (&gt;) 3.2 to 5.1 implied moderate to high disease activity and less than (&lt;) 2.6=remission.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="1.39"/>
                    <measurement group_id="O2" value="4.01" spread="1.38"/>
                    <measurement group_id="O3" value="4.31" spread="1.34"/>
                    <measurement group_id="O4" value="3.98" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Week 2, Month 1, 2 and 3</title>
        <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (milligram per liter [mg/L]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Baseline, Week 2, Month 1, 2, 3</time_frame>
        <population>FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Week 2, Month 1, 2 and 3</title>
          <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (milligram per liter [mg/L]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 239, 242, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" spread="0.90"/>
                    <measurement group_id="O2" value="5.60" spread="0.91"/>
                    <measurement group_id="O3" value="5.56" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n= 234, 231, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="1.12"/>
                    <measurement group_id="O2" value="4.42" spread="1.11"/>
                    <measurement group_id="O3" value="5.30" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n= 237, 236, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="1.12"/>
                    <measurement group_id="O2" value="3.99" spread="1.26"/>
                    <measurement group_id="O3" value="4.98" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n= 238, 233, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="1.26"/>
                    <measurement group_id="O2" value="3.64" spread="1.27"/>
                    <measurement group_id="O3" value="4.85" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 238, 229, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="1.27"/>
                    <measurement group_id="O2" value="3.59" spread="1.27"/>
                    <measurement group_id="O3" value="4.68" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 4, 5 and 6</title>
        <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Month 4, 5, 6</time_frame>
        <population>FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 4, 5 and 6</title>
          <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4 (n= 235, 222, 54, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" spread="1.24"/>
                    <measurement group_id="O2" value="3.26" spread="1.22"/>
                    <measurement group_id="O3" value="3.89" spread="1.19"/>
                    <measurement group_id="O4" value="3.50" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n= 231, 219, 55, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="1.26"/>
                    <measurement group_id="O2" value="3.12" spread="1.24"/>
                    <measurement group_id="O3" value="3.53" spread="1.25"/>
                    <measurement group_id="O4" value="3.34" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n= 228, 215, 53, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="1.23"/>
                    <measurement group_id="O2" value="3.11" spread="1.26"/>
                    <measurement group_id="O3" value="3.56" spread="1.32"/>
                    <measurement group_id="O4" value="3.12" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Week 2, Month 1, 2 and 3</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 functional categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3, 0=least functional difficulty and 3=extreme functional difficulty.</description>
        <time_frame>Baseline, Week 2, Month 1, 2, 3</time_frame>
        <population>FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Week 2, Month 1, 2 and 3</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 functional categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3, 0=least functional difficulty and 3=extreme functional difficulty.</description>
          <population>FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 240, 241, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.66"/>
                    <measurement group_id="O2" value="1.50" spread="0.64"/>
                    <measurement group_id="O3" value="1.53" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n= 240, 239, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.62"/>
                    <measurement group_id="O2" value="1.21" spread="0.65"/>
                    <measurement group_id="O3" value="1.43" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n= 237, 240, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.68"/>
                    <measurement group_id="O2" value="1.09" spread="0.66"/>
                    <measurement group_id="O3" value="1.40" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n= 240, 233, 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.66"/>
                    <measurement group_id="O2" value="0.97" spread="0.68"/>
                    <measurement group_id="O3" value="1.40" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 238, 229, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.70"/>
                    <measurement group_id="O2" value="0.97" spread="0.69"/>
                    <measurement group_id="O3" value="1.35" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire Disability Index (HAQ-DI) at Month 4, 5 and 6</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 functional categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3, 0=least functional difficulty and 3=extreme functional difficulty.</description>
        <time_frame>Month 4, 5, 6</time_frame>
        <population>FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire Disability Index (HAQ-DI) at Month 4, 5 and 6</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 functional categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3, 0=least functional difficulty and 3=extreme functional difficulty.</description>
          <population>FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4 (n= 235, 223, 55, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.66"/>
                    <measurement group_id="O2" value="0.88" spread="0.68"/>
                    <measurement group_id="O3" value="1.08" spread="0.70"/>
                    <measurement group_id="O4" value="1.09" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n= 231, 221, 55, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="0.69"/>
                    <measurement group_id="O2" value="0.87" spread="0.69"/>
                    <measurement group_id="O3" value="1.04" spread="0.59"/>
                    <measurement group_id="O4" value="1.03" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n= 229, 216, 54, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.68"/>
                    <measurement group_id="O2" value="0.86" spread="0.67"/>
                    <measurement group_id="O3" value="1.05" spread="0.63"/>
                    <measurement group_id="O4" value="1.00" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3</title>
        <description>Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (most severe pain), measurement on a scale corresponds to the magnitude of their pain.</description>
        <time_frame>Baseline, Week 2, Month 1, 2, 3</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3</title>
          <description>Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (most severe pain), measurement on a scale corresponds to the magnitude of their pain.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 241, 243, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.35" spread="22.27"/>
                    <measurement group_id="O2" value="62.03" spread="23.63"/>
                    <measurement group_id="O3" value="61.79" spread="21.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n= 239, 239, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.92" spread="22.87"/>
                    <measurement group_id="O2" value="42.13" spread="25.06"/>
                    <measurement group_id="O3" value="55.61" spread="23.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n= 237, 240, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.68" spread="23.04"/>
                    <measurement group_id="O2" value="36.86" spread="24.46"/>
                    <measurement group_id="O3" value="52.47" spread="24.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n= 240, 233, 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.39" spread="23.29"/>
                    <measurement group_id="O2" value="31.66" spread="24.38"/>
                    <measurement group_id="O3" value="52.38" spread="26.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 237, 228, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.93" spread="23.73"/>
                    <measurement group_id="O2" value="31.37" spread="24.35"/>
                    <measurement group_id="O3" value="49.84" spread="25.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Arthritis Pain at Month 4, 5 and 6</title>
        <description>Participants assessed the severity of their arthritis pain using a 100 mm visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (most severe pain), measurement on a scale corresponds to the magnitude of their pain.</description>
        <time_frame>Month 4, 5, 6</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Arthritis Pain at Month 4, 5 and 6</title>
          <description>Participants assessed the severity of their arthritis pain using a 100 mm visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (most severe pain), measurement on a scale corresponds to the magnitude of their pain.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4 (n= 235, 223, 55, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.18" spread="23.02"/>
                    <measurement group_id="O2" value="29.70" spread="23.21"/>
                    <measurement group_id="O3" value="34.27" spread="24.53"/>
                    <measurement group_id="O4" value="35.47" spread="25.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n= 231, 221, 55, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.63" spread="23.07"/>
                    <measurement group_id="O2" value="29.10" spread="22.24"/>
                    <measurement group_id="O3" value="34.05" spread="23.48"/>
                    <measurement group_id="O4" value="35.06" spread="24.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n= 228, 216, 54, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.60" spread="23.55"/>
                    <measurement group_id="O2" value="27.89" spread="23.17"/>
                    <measurement group_id="O3" value="33.96" spread="24.62"/>
                    <measurement group_id="O4" value="32.28" spread="23.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly.</description>
        <time_frame>Baseline, Week 2, Month 1, 2, 3</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 240, 243, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.66" spread="22.00"/>
                    <measurement group_id="O2" value="63.46" spread="23.23"/>
                    <measurement group_id="O3" value="62.63" spread="21.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n= 240, 239, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.34" spread="22.36"/>
                    <measurement group_id="O2" value="41.32" spread="24.90"/>
                    <measurement group_id="O3" value="55.95" spread="23.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n= 237, 240, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.63" spread="22.36"/>
                    <measurement group_id="O2" value="37.69" spread="23.94"/>
                    <measurement group_id="O3" value="53.23" spread="24.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n= 240, 233, 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.29" spread="22.20"/>
                    <measurement group_id="O2" value="32.56" spread="23.47"/>
                    <measurement group_id="O3" value="53.05" spread="26.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 238, 229, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.90" spread="23.61"/>
                    <measurement group_id="O2" value="32.78" spread="23.75"/>
                    <measurement group_id="O3" value="50.48" spread="25.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment (PtGA) of Arthritis Pain at Month 4, 5 and 6</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly.</description>
        <time_frame>Month 4, 5, 6</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment (PtGA) of Arthritis Pain at Month 4, 5 and 6</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4 (n= 235, 223, 55, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.59" spread="22.44"/>
                    <measurement group_id="O2" value="29.69" spread="22.25"/>
                    <measurement group_id="O3" value="35.27" spread="23.77"/>
                    <measurement group_id="O4" value="36.45" spread="25.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n= 231, 221, 55, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.59" spread="23.37"/>
                    <measurement group_id="O2" value="29.37" spread="22.13"/>
                    <measurement group_id="O3" value="32.88" spread="21.43"/>
                    <measurement group_id="O4" value="33.96" spread="25.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n= 228, 216, 54, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.56" spread="23.09"/>
                    <measurement group_id="O2" value="29.52" spread="22.89"/>
                    <measurement group_id="O3" value="33.51" spread="24.00"/>
                    <measurement group_id="O4" value="32.89" spread="23.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3</title>
        <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
        <time_frame>Baseline, Week 2, Month 1, 2, 3</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3</title>
          <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 241, 243, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.46" spread="16.93"/>
                    <measurement group_id="O2" value="60.84" spread="16.84"/>
                    <measurement group_id="O3" value="62.22" spread="16.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n= 239, 240, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.43" spread="17.69"/>
                    <measurement group_id="O2" value="40.47" spread="19.73"/>
                    <measurement group_id="O3" value="52.15" spread="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n= 237, 240, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.89" spread="18.91"/>
                    <measurement group_id="O2" value="33.99" spread="20.37"/>
                    <measurement group_id="O3" value="46.98" spread="22.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n= 240, 232, 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.06" spread="20.81"/>
                    <measurement group_id="O2" value="26.75" spread="19.23"/>
                    <measurement group_id="O3" value="44.45" spread="23.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 238, 229, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.20" spread="19.98"/>
                    <measurement group_id="O2" value="24.47" spread="18.42"/>
                    <measurement group_id="O3" value="42.05" spread="23.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment (PGA) of Arthritis Pain at Month 4, 5 and 6</title>
        <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
        <time_frame>Month 4, 5, 6</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment (PGA) of Arthritis Pain at Month 4, 5 and 6</title>
          <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4 (n= 235, 221, 54, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.30" spread="18.56"/>
                    <measurement group_id="O2" value="21.21" spread="16.46"/>
                    <measurement group_id="O3" value="27.48" spread="19.80"/>
                    <measurement group_id="O4" value="25.86" spread="20.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n= 231, 221, 55, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.60" spread="17.63"/>
                    <measurement group_id="O2" value="20.99" spread="16.13"/>
                    <measurement group_id="O3" value="24.74" spread="17.93"/>
                    <measurement group_id="O4" value="25.90" spread="19.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n= 229, 216, 54, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.26" spread="18.12"/>
                    <measurement group_id="O2" value="20.61" spread="16.27"/>
                    <measurement group_id="O3" value="26.16" spread="19.55"/>
                    <measurement group_id="O4" value="21.54" spread="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline:Physical functioning (n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.09" spread="9.31"/>
                    <measurement group_id="O2" value="30.51" spread="8.76"/>
                    <measurement group_id="O3" value="31.41" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Role Physical (n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.84" spread="8.87"/>
                    <measurement group_id="O2" value="33.45" spread="8.69"/>
                    <measurement group_id="O3" value="33.33" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Social Functioning (n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.78" spread="11.04"/>
                    <measurement group_id="O2" value="36.07" spread="11.27"/>
                    <measurement group_id="O3" value="35.16" spread="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Bodily Pain (n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.41" spread="7.57"/>
                    <measurement group_id="O2" value="32.74" spread="7.55"/>
                    <measurement group_id="O3" value="32.77" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Mental Health (n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.05" spread="11.49"/>
                    <measurement group_id="O2" value="40.50" spread="12.57"/>
                    <measurement group_id="O3" value="38.43" spread="12.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Role Emotional (n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.26" spread="12.63"/>
                    <measurement group_id="O2" value="36.70" spread="13.03"/>
                    <measurement group_id="O3" value="35.17" spread="13.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Vitality (n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.22" spread="10.06"/>
                    <measurement group_id="O2" value="41.04" spread="10.27"/>
                    <measurement group_id="O3" value="40.13" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:General health perception(n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.86" spread="8.72"/>
                    <measurement group_id="O2" value="35.71" spread="8.86"/>
                    <measurement group_id="O3" value="34.70" spread="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Mental Component (n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.36" spread="11.68"/>
                    <measurement group_id="O2" value="42.19" spread="12.44"/>
                    <measurement group_id="O3" value="39.87" spread="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Physical Component (n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.23" spread="8.03"/>
                    <measurement group_id="O2" value="31.37" spread="7.39"/>
                    <measurement group_id="O3" value="32.21" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Physical functioning(n=235,224,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.13" spread="10.44"/>
                    <measurement group_id="O2" value="37.05" spread="10.58"/>
                    <measurement group_id="O3" value="32.93" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Role Physical (n=233,224,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.90" spread="9.41"/>
                    <measurement group_id="O2" value="40.45" spread="9.90"/>
                    <measurement group_id="O3" value="35.19" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Social Functioning(n=235,224,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.62" spread="10.90"/>
                    <measurement group_id="O2" value="43.25" spread="9.95"/>
                    <measurement group_id="O3" value="36.14" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Bodily Pain (n=235,224,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.56" spread="9.38"/>
                    <measurement group_id="O2" value="43.08" spread="9.50"/>
                    <measurement group_id="O3" value="36.35" spread="8.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Mental Health (n=235,224,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.33" spread="11.50"/>
                    <measurement group_id="O2" value="45.13" spread="11.25"/>
                    <measurement group_id="O3" value="40.73" spread="10.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Role Emotional (n=233,224,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.76" spread="12.13"/>
                    <measurement group_id="O2" value="40.84" spread="11.57"/>
                    <measurement group_id="O3" value="36.08" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Vitality (n=235,224,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.36" spread="10.69"/>
                    <measurement group_id="O2" value="49.03" spread="9.86"/>
                    <measurement group_id="O3" value="42.23" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:General health perception(n=235,224,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.52" spread="9.37"/>
                    <measurement group_id="O2" value="41.50" spread="9.78"/>
                    <measurement group_id="O3" value="37.22" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Mental Component (n=233,224,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.21" spread="11.65"/>
                    <measurement group_id="O2" value="46.58" spread="10.81"/>
                    <measurement group_id="O3" value="41.13" spread="10.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Physical Component (n=233,224,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.03" spread="9.18"/>
                    <measurement group_id="O2" value="39.69" spread="9.31"/>
                    <measurement group_id="O3" value="34.58" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-Item Short-Form Health Survey (SF-36) at Month 6</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning.</description>
        <time_frame>Month 6</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>36-Item Short-Form Health Survey (SF-36) at Month 6</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.99" spread="10.07"/>
                    <measurement group_id="O2" value="38.43" spread="10.67"/>
                    <measurement group_id="O3" value="35.74" spread="10.23"/>
                    <measurement group_id="O4" value="35.26" spread="9.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.85" spread="9.57"/>
                    <measurement group_id="O2" value="40.93" spread="9.50"/>
                    <measurement group_id="O3" value="38.25" spread="9.73"/>
                    <measurement group_id="O4" value="38.97" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.36" spread="10.60"/>
                    <measurement group_id="O2" value="42.98" spread="10.15"/>
                    <measurement group_id="O3" value="39.57" spread="11.45"/>
                    <measurement group_id="O4" value="43.39" spread="9.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.80" spread="9.55"/>
                    <measurement group_id="O2" value="43.67" spread="9.54"/>
                    <measurement group_id="O3" value="40.80" spread="9.36"/>
                    <measurement group_id="O4" value="42.19" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.98" spread="12.18"/>
                    <measurement group_id="O2" value="45.05" spread="11.01"/>
                    <measurement group_id="O3" value="42.14" spread="11.90"/>
                    <measurement group_id="O4" value="47.03" spread="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.37" spread="11.32"/>
                    <measurement group_id="O2" value="41.03" spread="11.47"/>
                    <measurement group_id="O3" value="39.04" spread="12.93"/>
                    <measurement group_id="O4" value="42.66" spread="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.47" spread="10.58"/>
                    <measurement group_id="O2" value="48.89" spread="10.29"/>
                    <measurement group_id="O3" value="45.08" spread="9.50"/>
                    <measurement group_id="O4" value="47.88" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perception</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.05" spread="9.24"/>
                    <measurement group_id="O2" value="42.58" spread="9.84"/>
                    <measurement group_id="O3" value="38.99" spread="8.73"/>
                    <measurement group_id="O4" value="40.42" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.43" spread="11.58"/>
                    <measurement group_id="O2" value="46.08" spread="10.44"/>
                    <measurement group_id="O3" value="43.29" spread="12.37"/>
                    <measurement group_id="O4" value="48.76" spread="11.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.24" spread="8.42"/>
                    <measurement group_id="O2" value="40.89" spread="9.04"/>
                    <measurement group_id="O3" value="37.89" spread="9.56"/>
                    <measurement group_id="O4" value="37.06" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3</title>
        <description>Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more intensity of attribute.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3</title>
          <description>Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more intensity of attribute.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline:overall sleep problem(n=238,242,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.45" spread="18.38"/>
                    <measurement group_id="O2" value="43.09" spread="20.41"/>
                    <measurement group_id="O3" value="47.32" spread="21.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:sleep problem summary(n=239,242,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.59" spread="18.98"/>
                    <measurement group_id="O2" value="42.38" spread="21.01"/>
                    <measurement group_id="O3" value="45.98" spread="21.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:somnolence(n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.21" spread="22.47"/>
                    <measurement group_id="O2" value="37.64" spread="21.76"/>
                    <measurement group_id="O3" value="36.56" spread="21.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:snoring(n=238,243,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.71" spread="31.07"/>
                    <measurement group_id="O2" value="30.29" spread="30.50"/>
                    <measurement group_id="O3" value="30.25" spread="31.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:quantity(n=240,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.53" spread="1.56"/>
                    <measurement group_id="O2" value="6.38" spread="1.63"/>
                    <measurement group_id="O3" value="6.37" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:sleep disturbance(n=238,242,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.44" spread="24.11"/>
                    <measurement group_id="O2" value="43.33" spread="26.18"/>
                    <measurement group_id="O3" value="51.27" spread="25.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:awaken short of breath(n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.16" spread="23.76"/>
                    <measurement group_id="O2" value="20.91" spread="25.47"/>
                    <measurement group_id="O3" value="24.92" spread="29.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:adequacy(n=239,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.44" spread="27.25"/>
                    <measurement group_id="O2" value="42.63" spread="27.37"/>
                    <measurement group_id="O3" value="40.08" spread="28.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:overall sleep problem(n=236,228,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.53" spread="19.30"/>
                    <measurement group_id="O2" value="33.29" spread="19.96"/>
                    <measurement group_id="O3" value="41.13" spread="21.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:sleep problem summary(n=236,228,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.46" spread="19.89"/>
                    <measurement group_id="O2" value="33.25" spread="20.16"/>
                    <measurement group_id="O3" value="40.55" spread="22.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:somnolence(n=236,229,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.28" spread="21.28"/>
                    <measurement group_id="O2" value="30.45" spread="21.26"/>
                    <measurement group_id="O3" value="35.66" spread="23.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:snoring(n=236,229,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.63" spread="29.61"/>
                    <measurement group_id="O2" value="25.85" spread="27.57"/>
                    <measurement group_id="O3" value="27.52" spread="29.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:quantity(n=237,228,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.77" spread="1.63"/>
                    <measurement group_id="O2" value="6.89" spread="1.45"/>
                    <measurement group_id="O3" value="6.78" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:sleep disturbance(n=236,229,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.58" spread="24.67"/>
                    <measurement group_id="O2" value="32.58" spread="24.27"/>
                    <measurement group_id="O3" value="41.16" spread="27.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:awaken short of breath(n=236,228,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.93" spread="21.29"/>
                    <measurement group_id="O2" value="16.23" spread="21.69"/>
                    <measurement group_id="O3" value="22.20" spread="24.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:adequacy(n=236,229,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.69" spread="28.77"/>
                    <measurement group_id="O2" value="52.93" spread="27.75"/>
                    <measurement group_id="O3" value="44.40" spread="27.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline and Month 3</title>
        <description>MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline and Month 3</title>
          <description>MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.</description>
          <population>FAS population. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline(n=241,243,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3(n=238,229,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Outcome Study Sleep Scale (MOS-SS) at Month 6</title>
        <description>Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more intensity of attribute.</description>
        <time_frame>Month 6</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Outcome Study Sleep Scale (MOS-SS) at Month 6</title>
          <description>Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more intensity of attribute.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall sleep problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.68" spread="18.80"/>
                    <measurement group_id="O2" value="33.33" spread="19.19"/>
                    <measurement group_id="O3" value="37.29" spread="19.26"/>
                    <measurement group_id="O4" value="35.64" spread="21.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep problem summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.17" spread="18.81"/>
                    <measurement group_id="O2" value="33.33" spread="19.66"/>
                    <measurement group_id="O3" value="37.41" spread="20.30"/>
                    <measurement group_id="O4" value="35.87" spread="20.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.26" spread="21.01"/>
                    <measurement group_id="O2" value="29.42" spread="20.64"/>
                    <measurement group_id="O3" value="31.36" spread="19.75"/>
                    <measurement group_id="O4" value="29.60" spread="21.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Snoring</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.28" spread="31.04"/>
                    <measurement group_id="O2" value="27.79" spread="28.24"/>
                    <measurement group_id="O3" value="26.30" spread="28.50"/>
                    <measurement group_id="O4" value="29.20" spread="27.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quantity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.64" spread="1.45"/>
                    <measurement group_id="O2" value="6.87" spread="1.71"/>
                    <measurement group_id="O3" value="6.65" spread="1.52"/>
                    <measurement group_id="O4" value="6.64" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep disturbance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.75" spread="25.11"/>
                    <measurement group_id="O2" value="33.38" spread="23.91"/>
                    <measurement group_id="O3" value="37.80" spread="23.96"/>
                    <measurement group_id="O4" value="33.80" spread="25.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Awaken short of breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.55" spread="21.67"/>
                    <measurement group_id="O2" value="15.70" spread="21.41"/>
                    <measurement group_id="O3" value="21.11" spread="21.43"/>
                    <measurement group_id="O4" value="23.20" spread="25.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adequacy(n=229,214,54,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.52" spread="27.41"/>
                    <measurement group_id="O2" value="53.04" spread="29.14"/>
                    <measurement group_id="O3" value="49.44" spread="29.36"/>
                    <measurement group_id="O4" value="49.00" spread="27.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Month 6</title>
        <description>MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.</description>
        <time_frame>Month 6</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Month 6</title>
          <description>MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Baseline and Month 3</title>
        <description>FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Baseline and Month 3</title>
          <description>FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 240, 243, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.90" spread="10.70"/>
                    <measurement group_id="O2" value="27.72" spread="11.15"/>
                    <measurement group_id="O3" value="27.17" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 237, 227, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.40" spread="10.65"/>
                    <measurement group_id="O2" value="35.42" spread="9.75"/>
                    <measurement group_id="O3" value="30.06" spread="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Month 6</title>
        <description>FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
        <time_frame>Month 6</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Month 6</title>
          <description>FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.58" spread="10.69"/>
                    <measurement group_id="O2" value="36.30" spread="10.10"/>
                    <measurement group_id="O3" value="33.63" spread="9.29"/>
                    <measurement group_id="O4" value="36.46" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Baseline and Month 3</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Baseline and Month 3</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 240, 243, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.32"/>
                    <measurement group_id="O2" value="0.39" spread="0.32"/>
                    <measurement group_id="O3" value="0.42" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 237, 227, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.25"/>
                    <measurement group_id="O2" value="0.66" spread="0.23"/>
                    <measurement group_id="O3" value="0.51" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Month 6</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Month 6</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Month 6</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.23"/>
                    <measurement group_id="O2" value="0.68" spread="0.22"/>
                    <measurement group_id="O3" value="0.58" spread="0.29"/>
                    <measurement group_id="O4" value="0.65" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3</title>
        <description>Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor,non-medical practitioner,nursing home,hospital,surgery,emergency room(ER) treatment,diagnostic tests, over-night stay,home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status,willingness to work,work disability due to RA,sick leave,part time work,ability to perform chores,chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. Participants with at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint were included. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3</title>
          <description>Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor,non-medical practitioner,nursing home,hospital,surgery,emergency room(ER) treatment,diagnostic tests, over-night stay,home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status,willingness to work,work disability due to RA,sick leave,part time work,ability to perform chores,chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.</description>
          <population>FAS population. Participants with at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint were included. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline:Seen any doctor(n=236,239,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.39"/>
                    <measurement group_id="O2" value="1.15" spread="0.36"/>
                    <measurement group_id="O3" value="1.17" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Treated in emergency room(n=236,239,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.23"/>
                    <measurement group_id="O2" value="1.92" spread="0.26"/>
                    <measurement group_id="O3" value="1.92" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Admitted for overnight stay (n=13,18,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.55"/>
                    <measurement group_id="O2" value="0.17" spread="0.51"/>
                    <measurement group_id="O3" value="0.20" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Hospitalization(n=236,239,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.24"/>
                    <measurement group_id="O2" value="1.92" spread="0.27"/>
                    <measurement group_id="O3" value="1.94" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Outpatient surgery(n=236,239,120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.16"/>
                    <measurement group_id="O2" value="1.95" spread="0.21"/>
                    <measurement group_id="O3" value="1.98" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Non-study diagnostic test(n=235,239,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.38"/>
                    <measurement group_id="O2" value="1.78" spread="0.41"/>
                    <measurement group_id="O3" value="1.83" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:In nursing home(n=236,239,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.13"/>
                    <measurement group_id="O2" value="1.99" spread="0.09"/>
                    <measurement group_id="O3" value="1.99" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Home healthcare services(n=235,239,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.09"/>
                    <measurement group_id="O2" value="1.98" spread="0.13"/>
                    <measurement group_id="O3" value="1.99" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Required aids/devices(n=236,239,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="0.37"/>
                    <measurement group_id="O2" value="1.87" spread="0.34"/>
                    <measurement group_id="O3" value="1.83" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Non-medical practitioner(n=236,239,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.18"/>
                    <measurement group_id="O2" value="1.99" spread="0.09"/>
                    <measurement group_id="O3" value="1.98" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Currently employed(n=236,239,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.46"/>
                    <measurement group_id="O2" value="1.64" spread="0.48"/>
                    <measurement group_id="O3" value="1.64" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Feel well enough to work(n=111,90,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="0.35"/>
                    <measurement group_id="O2" value="1.83" spread="0.37"/>
                    <measurement group_id="O3" value="1.86" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Unable to work due to RA(n=111,93,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.48"/>
                    <measurement group_id="O2" value="1.29" spread="0.46"/>
                    <measurement group_id="O3" value="1.41" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Lost job/retired early(n=110,92,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.49"/>
                    <measurement group_id="O2" value="1.55" spread="0.50"/>
                    <measurement group_id="O3" value="1.55" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Work disabled due to RA(n=111,91,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.50"/>
                    <measurement group_id="O2" value="1.48" spread="0.50"/>
                    <measurement group_id="O3" value="1.52" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Retired(n=116,99,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.50"/>
                    <measurement group_id="O2" value="1.57" spread="0.50"/>
                    <measurement group_id="O3" value="1.49" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Sick leave due to RA(n=191,202,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.38"/>
                    <measurement group_id="O2" value="1.83" spread="0.38"/>
                    <measurement group_id="O3" value="1.74" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Performed part time work(n=192,202,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.31"/>
                    <measurement group_id="O2" value="1.87" spread="0.34"/>
                    <measurement group_id="O3" value="1.88" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Performed paid work(n=191,204,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.48"/>
                    <measurement group_id="O2" value="1.66" spread="0.48"/>
                    <measurement group_id="O3" value="1.62" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Unable to do chores(n=235,238,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.48"/>
                    <measurement group_id="O2" value="1.32" spread="0.47"/>
                    <measurement group_id="O3" value="1.30" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Chores by housekeeper(n=235,239,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="0.35"/>
                    <measurement group_id="O2" value="1.82" spread="0.39"/>
                    <measurement group_id="O3" value="1.81" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Chores by family/friends(n=235,239,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.49"/>
                    <measurement group_id="O2" value="1.44" spread="0.50"/>
                    <measurement group_id="O3" value="1.29" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Seen any doctor(n=235,228,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.49"/>
                    <measurement group_id="O2" value="1.41" spread="0.49"/>
                    <measurement group_id="O3" value="1.39" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Treated in emergency room(n=236,229,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.24"/>
                    <measurement group_id="O2" value="1.94" spread="0.24"/>
                    <measurement group_id="O3" value="1.93" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Admitted for overnight stay (n=14,14,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.61"/>
                    <measurement group_id="O2" value="0.43" spread="0.65"/>
                    <measurement group_id="O3" value="0.50" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Hospitalization(n=236,228,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.09"/>
                    <measurement group_id="O2" value="1.97" spread="0.16"/>
                    <measurement group_id="O3" value="1.98" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Outpatient surgery(n=236,229,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.17"/>
                    <measurement group_id="O2" value="1.98" spread="0.15"/>
                    <measurement group_id="O3" value="1.98" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Non-study diagnostic test(n=236,228,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.33"/>
                    <measurement group_id="O2" value="1.88" spread="0.32"/>
                    <measurement group_id="O3" value="1.87" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: In nursing home(n=236,229,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.00"/>
                    <measurement group_id="O2" value="2.00" spread="0.07"/>
                    <measurement group_id="O3" value="1.99" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Home healthcare services(n=236,228,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.09"/>
                    <measurement group_id="O2" value="2.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.99" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Required aids/devices(n=235,228,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.32"/>
                    <measurement group_id="O2" value="1.91" spread="0.28"/>
                    <measurement group_id="O3" value="1.87" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Non-medical practitioner(n=236,229,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.13"/>
                    <measurement group_id="O2" value="2.00" spread="0.07"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Currently employed(n=236,228,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.45"/>
                    <measurement group_id="O2" value="1.65" spread="0.48"/>
                    <measurement group_id="O3" value="1.62" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Feel well enough to work(n=108,93,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.45"/>
                    <measurement group_id="O2" value="1.69" spread="0.47"/>
                    <measurement group_id="O3" value="1.86" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Unable to work due to RA(n=107,98,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.50"/>
                    <measurement group_id="O2" value="1.48" spread="0.50"/>
                    <measurement group_id="O3" value="1.35" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Lost job/retired early(n=107,92,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.47"/>
                    <measurement group_id="O2" value="1.70" spread="0.46"/>
                    <measurement group_id="O3" value="1.59" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Work disabled due to RA(n=109,92,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.50"/>
                    <measurement group_id="O2" value="1.62" spread="0.49"/>
                    <measurement group_id="O3" value="1.47" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Retired(n=115,107,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="0.50"/>
                    <measurement group_id="O2" value="1.51" spread="0.50"/>
                    <measurement group_id="O3" value="1.53" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Sick leave due to RA(n=180,183,88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.26"/>
                    <measurement group_id="O2" value="1.91" spread="0.29"/>
                    <measurement group_id="O3" value="1.89" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Performed part time work(n=181,180,88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.23"/>
                    <measurement group_id="O2" value="1.94" spread="0.24"/>
                    <measurement group_id="O3" value="1.90" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Performed paid work(n=179,184,88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.44"/>
                    <measurement group_id="O2" value="1.76" spread="0.43"/>
                    <measurement group_id="O3" value="1.65" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Unable to do chores(n=231,227,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.49"/>
                    <measurement group_id="O2" value="1.63" spread="0.49"/>
                    <measurement group_id="O3" value="1.39" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Chores by housekeeper(n=235,229,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.32"/>
                    <measurement group_id="O2" value="1.92" spread="0.28"/>
                    <measurement group_id="O3" value="1.79" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Chores by family/friends(n=234,229,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.48"/>
                    <measurement group_id="O2" value="1.64" spread="0.48"/>
                    <measurement group_id="O3" value="1.49" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6</title>
        <description>Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor,non-medical practitioner,nursing home,hospital,surgery,emergency room(ER) treatment,diagnostic tests, over-night stay,home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status,willingness to work,work disability due to RA,sick leave,part time work,ability to perform chores,chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.</description>
        <time_frame>Month 6</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6</title>
          <description>Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor,non-medical practitioner,nursing home,hospital,surgery,emergency room(ER) treatment,diagnostic tests, over-night stay,home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status,willingness to work,work disability due to RA,sick leave,part time work,ability to perform chores,chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6:Seen any doctor(n=227,216,54,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.46"/>
                    <measurement group_id="O2" value="1.30" spread="0.46"/>
                    <measurement group_id="O3" value="1.28" spread="0.45"/>
                    <measurement group_id="O4" value="1.28" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Treated in emergency room(n=229,216,54,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.26"/>
                    <measurement group_id="O2" value="1.94" spread="0.24"/>
                    <measurement group_id="O3" value="1.94" spread="0.23"/>
                    <measurement group_id="O4" value="1.96" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Admitted for overnight stay (n=16,13,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.58"/>
                    <measurement group_id="O2" value="0.23" spread="0.44"/>
                    <measurement group_id="O3" value="1.33" spread="2.31"/>
                    <measurement group_id="O4" value="1.00" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Hospitalization(n=229,216,54,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="1.15"/>
                    <measurement group_id="O2" value="1.99" spread="1.12"/>
                    <measurement group_id="O3" value="1.96" spread="1.19"/>
                    <measurement group_id="O4" value="1.96" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Outpatient surgery(n=229,216,54,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.11"/>
                    <measurement group_id="O2" value="1.94" spread="0.23"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="1.96" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Diagnostic test(n=229,216,54,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.34"/>
                    <measurement group_id="O2" value="1.84" spread="0.37"/>
                    <measurement group_id="O3" value="1.87" spread="0.34"/>
                    <measurement group_id="O4" value="1.88" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:In nursing home(n=229,216,54,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.07"/>
                    <measurement group_id="O2" value="2.00" spread="0.07"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="2.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Home healthcare services(n=229,216,54,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.11"/>
                    <measurement group_id="O2" value="2.00" spread="0.07"/>
                    <measurement group_id="O3" value="1.96" spread="0.19"/>
                    <measurement group_id="O4" value="1.98" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Required aids/devices(n=229,216,54,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.31"/>
                    <measurement group_id="O2" value="1.94" spread="0.24"/>
                    <measurement group_id="O3" value="1.89" spread="0.32"/>
                    <measurement group_id="O4" value="1.92" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Non-medical practitioner(n=229,216,54,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.00"/>
                    <measurement group_id="O2" value="1.99" spread="0.10"/>
                    <measurement group_id="O3" value="1.98" spread="0.14"/>
                    <measurement group_id="O4" value="2.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Currently employed(n=229,216,54,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.46"/>
                    <measurement group_id="O2" value="1.65" spread="0.48"/>
                    <measurement group_id="O3" value="1.59" spread="0.50"/>
                    <measurement group_id="O4" value="1.58" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Feel well enough to work(n=124,101,24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.45"/>
                    <measurement group_id="O2" value="1.66" spread="0.47"/>
                    <measurement group_id="O3" value="1.71" spread="0.46"/>
                    <measurement group_id="O4" value="1.73" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Unable to work due to RA(n=123,105,24,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.50"/>
                    <measurement group_id="O2" value="1.46" spread="0.50"/>
                    <measurement group_id="O3" value="1.54" spread="0.51"/>
                    <measurement group_id="O4" value="1.42" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Lost job/retired early(n=126,102,24,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.45"/>
                    <measurement group_id="O2" value="1.63" spread="0.49"/>
                    <measurement group_id="O3" value="1.54" spread="0.51"/>
                    <measurement group_id="O4" value="1.57" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Work disabled due to RA(n=125,103,24,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.49"/>
                    <measurement group_id="O2" value="1.54" spread="0.50"/>
                    <measurement group_id="O3" value="1.54" spread="0.51"/>
                    <measurement group_id="O4" value="1.43" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Retired(n=126,110,25,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.50"/>
                    <measurement group_id="O2" value="1.45" spread="0.50"/>
                    <measurement group_id="O3" value="1.56" spread="0.51"/>
                    <measurement group_id="O4" value="1.48" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Sick leave due to RA(n=175,169,41,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.23"/>
                    <measurement group_id="O2" value="1.94" spread="0.24"/>
                    <measurement group_id="O3" value="1.93" spread="0.26"/>
                    <measurement group_id="O4" value="1.95" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Performed part time work(n=173,170,40,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.25"/>
                    <measurement group_id="O2" value="1.96" spread="0.19"/>
                    <measurement group_id="O3" value="1.93" spread="0.27"/>
                    <measurement group_id="O4" value="1.95" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Performed paid work(n=172,169,39,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.40"/>
                    <measurement group_id="O2" value="1.80" spread="0.40"/>
                    <measurement group_id="O3" value="1.64" spread="0.49"/>
                    <measurement group_id="O4" value="1.73" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Unable to do chores(n=229,214,52,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.49"/>
                    <measurement group_id="O2" value="1.69" spread="0.46"/>
                    <measurement group_id="O3" value="1.54" spread="0.50"/>
                    <measurement group_id="O4" value="1.70" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Chores by housekeeper(n=229,216,54,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.31"/>
                    <measurement group_id="O2" value="1.94" spread="0.25"/>
                    <measurement group_id="O3" value="1.85" spread="0.36"/>
                    <measurement group_id="O4" value="1.98" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Chores by family/friends(n=229,216,54,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.47"/>
                    <measurement group_id="O2" value="1.70" spread="0.46"/>
                    <measurement group_id="O3" value="1.54" spread="0.50"/>
                    <measurement group_id="O4" value="1.74" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3</title>
        <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3</title>
          <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline:Doctor visit(n=193,204,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" spread="4.50"/>
                    <measurement group_id="O2" value="3.85" spread="4.07"/>
                    <measurement group_id="O3" value="3.56" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:RA related doctor visit (n=192,205,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="0.81"/>
                    <measurement group_id="O2" value="1.18" spread="0.85"/>
                    <measurement group_id="O3" value="1.33" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Hospital ER visit(n=13,18,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.38"/>
                    <measurement group_id="O2" value="1.61" spread="1.29"/>
                    <measurement group_id="O3" value="1.40" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:RA related ER visit(n=12,18,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.75"/>
                    <measurement group_id="O2" value="0.50" spread="0.62"/>
                    <measurement group_id="O3" value="0.80" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Hospitalization(n=14,19,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.27"/>
                    <measurement group_id="O2" value="1.11" spread="0.32"/>
                    <measurement group_id="O3" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:RA related hospitalization(n=14,19,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.55"/>
                    <measurement group_id="O2" value="0.84" spread="0.60"/>
                    <measurement group_id="O3" value="0.88" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Outpatient surgery(n=6,11,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.00"/>
                    <measurement group_id="O2" value="1.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:RA related outpatient surgery(n=6,11,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.55" spread="0.82"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Non-study diagnostic test(n=39,51,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="1.22"/>
                    <measurement group_id="O2" value="1.94" spread="1.22"/>
                    <measurement group_id="O3" value="1.59" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:RA related diagnostic test(n=41,52,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.67"/>
                    <measurement group_id="O2" value="0.83" spread="0.94"/>
                    <measurement group_id="O3" value="0.95" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Non-medical practitioner visit(n=8,2,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.00" spread="12.99"/>
                    <measurement group_id="O2" value="7.00" spread="7.07"/>
                    <measurement group_id="O3" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:RA related non-medical visit(n=8,2,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.64"/>
                    <measurement group_id="O2" value="1.50" spread="0.71"/>
                    <measurement group_id="O3" value="0.50" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Doctor visit(n=141,137,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="2.40"/>
                    <measurement group_id="O2" value="3.64" spread="3.44"/>
                    <measurement group_id="O3" value="4.00" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:RA related doctor visit(n=142,138,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.67"/>
                    <measurement group_id="O2" value="0.81" spread="0.81"/>
                    <measurement group_id="O3" value="0.92" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Hospital ER visit(n=14,14,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="0.80"/>
                    <measurement group_id="O2" value="1.29" spread="0.47"/>
                    <measurement group_id="O3" value="1.50" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:RA related ER visit(n=14,13,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.53"/>
                    <measurement group_id="O2" value="0.15" spread="0.55"/>
                    <measurement group_id="O3" value="0.25" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Hospitalization(n=2,6,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.00"/>
                    <measurement group_id="O2" value="1.17" spread="0.41"/>
                    <measurement group_id="O3" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:RA related hospitalization(n=2,7,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.71"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Outpatient surgery(n=7,5,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.38"/>
                    <measurement group_id="O2" value="1.60" spread="0.89"/>
                    <measurement group_id="O3" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:RA related outpatient surgery(n=7,5,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.76"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.00" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Non-study diagnostic test(n=27,25,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="0.81"/>
                    <measurement group_id="O2" value="1.60" spread="0.82"/>
                    <measurement group_id="O3" value="1.54" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:RA related diagnostic test(n=30,26,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.35"/>
                    <measurement group_id="O2" value="0.15" spread="0.37"/>
                    <measurement group_id="O3" value="0.21" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Non-medical practitioner visit(n=4,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.75" spread="6.99"/>
                    <measurement group_id="O2" value="7.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:RA related non-medical visit(n=4,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.50"/>
                    <measurement group_id="O2" value="2.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6</title>
        <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.</description>
        <time_frame>Month 6</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6</title>
          <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Doctor visit(n=159,152,39,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="2.54"/>
                    <measurement group_id="O2" value="3.69" spread="3.18"/>
                    <measurement group_id="O3" value="3.00" spread="2.29"/>
                    <measurement group_id="O4" value="3.69" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related doctor visit(n=159,152,39,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.70"/>
                    <measurement group_id="O2" value="0.83" spread="0.73"/>
                    <measurement group_id="O3" value="1.05" spread="0.60"/>
                    <measurement group_id="O4" value="0.92" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital ER visit(n=16,13,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="0.25"/>
                    <measurement group_id="O2" value="1.25" spread="0.45"/>
                    <measurement group_id="O3" value="3.00" spread="1.73"/>
                    <measurement group_id="O4" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related ER visit(n=16,12,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.34"/>
                    <measurement group_id="O2" value="0.08" spread="0.28"/>
                    <measurement group_id="O3" value="1.67" spread="2.08"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization(n=5,3,2,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="0.45"/>
                    <measurement group_id="O2" value="1.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.50" spread="0.71"/>
                    <measurement group_id="O4" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related hospitalization(n=5,3,2,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.45"/>
                    <measurement group_id="O2" value="0.33" spread="0.58"/>
                    <measurement group_id="O3" value="0.50" spread="0.71"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient surgery(n=3,10,0,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.00"/>
                    <measurement group_id="O2" value="1.50" spread="1.58"/>
                    <measurement group_id="O3" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                    <measurement group_id="O4" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related outpatient surgery(n=3,12,0,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-study diagnostic test(n=24,33,7,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="1.55"/>
                    <measurement group_id="O2" value="1.39" spread="0.75"/>
                    <measurement group_id="O3" value="2.57" spread="1.62"/>
                    <measurement group_id="O4" value="1.20" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related diagnostic test(n=29,34,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.87"/>
                    <measurement group_id="O2" value="0.29" spread="0.52"/>
                    <measurement group_id="O3" value="0.67" spread="0.82"/>
                    <measurement group_id="O4" value="0.33" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-medical practitioner visit(n=0,2,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                    <measurement group_id="O2" value="3.00" spread="1.41"/>
                    <measurement group_id="O3" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                    <measurement group_id="O4" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related non-medical visit(n=0,2,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                    <measurement group_id="O2" value="0.50" spread="0.71"/>
                    <measurement group_id="O3" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                    <measurement group_id="O4" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days as Assessed Using RA-HCRU at Baseline and Month 3</title>
        <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days as Assessed Using RA-HCRU at Baseline and Month 3</title>
          <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline:Hospital length of stay(n=14,19,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.43" spread="12.33"/>
                    <measurement group_id="O2" value="9.63" spread="7.27"/>
                    <measurement group_id="O3" value="4.29" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Days in nursing home(n=4,2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.25" spread="2.63"/>
                    <measurement group_id="O2" value="16.50" spread="6.36"/>
                    <measurement group_id="O3" value="10.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Days devices/aids used(n=37,31,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.95" spread="134.74"/>
                    <measurement group_id="O2" value="85.52" spread="95.38"/>
                    <measurement group_id="O3" value="55.90" spread="56.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:RA related aids used(n=38,31,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="1.47"/>
                    <measurement group_id="O2" value="1.90" spread="1.33"/>
                    <measurement group_id="O3" value="1.45" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Days of work per week(n=72,84,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread="1.04"/>
                    <measurement group_id="O2" value="4.92" spread="1.17"/>
                    <measurement group_id="O3" value="5.02" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Days on sick leave(n=33,34,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.12" spread="33.23"/>
                    <measurement group_id="O2" value="10.91" spread="18.15"/>
                    <measurement group_id="O3" value="22.40" spread="29.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Days of part time work(n=20,25,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.65" spread="22.74"/>
                    <measurement group_id="O2" value="20.44" spread="26.71"/>
                    <measurement group_id="O3" value="12.42" spread="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Paid work, bothered by RA(n=69,68,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.87" spread="31.01"/>
                    <measurement group_id="O2" value="28.15" spread="29.06"/>
                    <measurement group_id="O3" value="38.30" spread="27.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Chores by housekeeper(n=33,43,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.30" spread="24.67"/>
                    <measurement group_id="O2" value="16.63" spread="25.99"/>
                    <measurement group_id="O3" value="14.55" spread="22.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Chores by family(n=139,131,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.54" spread="31.72"/>
                    <measurement group_id="O2" value="27.85" spread="34.80"/>
                    <measurement group_id="O3" value="22.12" spread="27.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Hospital length of stay(n=2,6,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.50" spread="6.36"/>
                    <measurement group_id="O2" value="6.33" spread="7.12"/>
                    <measurement group_id="O3" value="12.00" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Days in nursing home(n=0,1,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                    <measurement group_id="O2" value="2.0">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="10.0">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Days devices/aids used(n=27,20,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.93" spread="107.85"/>
                    <measurement group_id="O2" value="89.50" spread="89.98"/>
                    <measurement group_id="O3" value="94.68" spread="111.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:RA related aids used(n=27,20,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="1.36"/>
                    <measurement group_id="O2" value="1.50" spread="0.95"/>
                    <measurement group_id="O3" value="1.93" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Days of work per week(n=68,79,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="0.93"/>
                    <measurement group_id="O2" value="5.05" spread="1.19"/>
                    <measurement group_id="O3" value="4.88" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Days on sick leave(n=13,17,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.00" spread="23.59"/>
                    <measurement group_id="O2" value="14.82" spread="23.32"/>
                    <measurement group_id="O3" value="19.60" spread="27.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Days of part time work(n=10,11,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.70" spread="20.97"/>
                    <measurement group_id="O2" value="19.09" spread="25.07"/>
                    <measurement group_id="O3" value="6.22" spread="5.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Paid work, bothered by RA(n=44,44,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.70" spread="26.22"/>
                    <measurement group_id="O2" value="19.39" spread="23.10"/>
                    <measurement group_id="O3" value="26.50" spread="27.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Chores by housekeeper(n=26,19,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.73" spread="8.43"/>
                    <measurement group_id="O2" value="6.32" spread="5.73"/>
                    <measurement group_id="O3" value="18.13" spread="25.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Chores by family(n=81,82,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.72" spread="31.12"/>
                    <measurement group_id="O2" value="27.29" spread="33.02"/>
                    <measurement group_id="O3" value="27.00" spread="30.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days as Assessed Using RA-HCRU at Month 6</title>
        <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.</description>
        <time_frame>Month 6</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days as Assessed Using RA-HCRU at Month 6</title>
          <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospital length of stay(n=5,3,2,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.60" spread="18.28"/>
                    <measurement group_id="O2" value="7.67" spread="5.86"/>
                    <measurement group_id="O3" value="13.50" spread="14.85"/>
                    <measurement group_id="O4" value="1.50" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days in nursing home(n=1,1,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                    <measurement group_id="O2" value="15.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                    <measurement group_id="O4" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days devices/aids used(n=24,13,6,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.17" spread="116.84"/>
                    <measurement group_id="O2" value="53.85" spread="52.29"/>
                    <measurement group_id="O3" value="101.50" spread="106.85"/>
                    <measurement group_id="O4" value="72.25" spread="113.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related aids used(n=25,12,6,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="1.23"/>
                    <measurement group_id="O2" value="1.67" spread="0.98"/>
                    <measurement group_id="O3" value="2.17" spread="1.83"/>
                    <measurement group_id="O4" value="1.75" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days of work per week(n=65,75,22,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95" spread="0.84"/>
                    <measurement group_id="O2" value="5.16" spread="0.99"/>
                    <measurement group_id="O3" value="5.09" spread="1.15"/>
                    <measurement group_id="O4" value="4.71" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days on sick leave(n=10,10,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.10" spread="27.23"/>
                    <measurement group_id="O2" value="15.50" spread="27.71"/>
                    <measurement group_id="O3" value="9.00" spread="5.20"/>
                    <measurement group_id="O4" value="47.50" spread="60.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days of part time work(n=11,6,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.00" spread="25.46"/>
                    <measurement group_id="O2" value="8.50" spread="5.68"/>
                    <measurement group_id="O3" value="5.00" spread="3.00"/>
                    <measurement group_id="O4" value="4.00" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paid work, bothered by RA(n=34,32,14,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.09" spread="25.89"/>
                    <measurement group_id="O2" value="12.72" spread="17.50"/>
                    <measurement group_id="O3" value="26.14" spread="29.98"/>
                    <measurement group_id="O4" value="15.92" spread="18.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chores by housekeeper(n=25,13,8,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.32" spread="24.40"/>
                    <measurement group_id="O2" value="20.23" spread="31.76"/>
                    <measurement group_id="O3" value="8.50" spread="11.78"/>
                    <measurement group_id="O4" value="90.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chores by family(n=74,64,24,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.38" spread="27.42"/>
                    <measurement group_id="O2" value="28.09" spread="32.55"/>
                    <measurement group_id="O3" value="11.58" spread="18.35"/>
                    <measurement group_id="O4" value="27.38" spread="30.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3</title>
        <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3</title>
          <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>hours per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline:Home healthcare services(n=1,4,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                    <measurement group_id="O2" value="3.75" spread="5.50"/>
                    <measurement group_id="O3" value="1.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:RA related home HC services(n=2,4,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.71"/>
                    <measurement group_id="O2" value="2.25" spread="2.50"/>
                    <measurement group_id="O3" value="1.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Work done(n=71,85,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.66" spread="1.87"/>
                    <measurement group_id="O2" value="8.60" spread="6.12"/>
                    <measurement group_id="O3" value="8.95" spread="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Missed work due to RA(n=19,25,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" spread="2.67"/>
                    <measurement group_id="O2" value="10.84" spread="24.54"/>
                    <measurement group_id="O3" value="6.17" spread="12.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Chores by housekeeper(n=33,43,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64" spread="4.06"/>
                    <measurement group_id="O2" value="4.67" spread="2.07"/>
                    <measurement group_id="O3" value="5.86" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Chores by family(n=139,131,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.99" spread="4.02"/>
                    <measurement group_id="O2" value="3.32" spread="2.89"/>
                    <measurement group_id="O3" value="4.85" spread="6.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Home healthcare services(n=2,0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="2.12"/>
                    <measurement group_id="O2" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                    <measurement group_id="O3" value="1.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:RA related home HC services(n=2,0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.71"/>
                    <measurement group_id="O2" value="NA">Data was not analyzed as no participant was evaluable for this parameter.</measurement>
                    <measurement group_id="O3" value="0.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Work done(n=66,79,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.20" spread="7.28"/>
                    <measurement group_id="O2" value="7.68" spread="2.37"/>
                    <measurement group_id="O3" value="8.85" spread="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Missed work due to RA(n=10,9,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" spread="1.55"/>
                    <measurement group_id="O2" value="3.67" spread="1.41"/>
                    <measurement group_id="O3" value="9.56" spread="19.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Chores by housekeeper(n=27,19,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.74" spread="4.70"/>
                    <measurement group_id="O2" value="5.21" spread="4.89"/>
                    <measurement group_id="O3" value="5.91" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Chores by family(n=79,82,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="1.96"/>
                    <measurement group_id="O2" value="3.82" spread="6.91"/>
                    <measurement group_id="O3" value="3.69" spread="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hours Per Days as Assessed Using RA-HCRU at Month 6</title>
        <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.</description>
        <time_frame>Month 6</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hours Per Days as Assessed Using RA-HCRU at Month 6</title>
          <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>hours per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Home healthcare services(n=3,1,1,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="1.00"/>
                    <measurement group_id="O2" value="1.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="0.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="1.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related home healthcare services(3,1,2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.00"/>
                    <measurement group_id="O2" value="1.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work done(n=65,75,22,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.38" spread="5.53"/>
                    <measurement group_id="O2" value="8.43" spread="4.16"/>
                    <measurement group_id="O3" value="7.23" spread="2.11"/>
                    <measurement group_id="O4" value="8.29" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missed work due to RA(n=11,7,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="2.53"/>
                    <measurement group_id="O2" value="2.57" spread="1.72"/>
                    <measurement group_id="O3" value="2.67" spread="2.31"/>
                    <measurement group_id="O4" value="1.50" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chores by housekeeper(n=24,14,8,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.13" spread="2.49"/>
                    <measurement group_id="O2" value="10.57" spread="22.97"/>
                    <measurement group_id="O3" value="5.00" spread="2.45"/>
                    <measurement group_id="O4" value="8.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chores by family(n=74,64,24,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" spread="2.18"/>
                    <measurement group_id="O2" value="2.86" spread="1.80"/>
                    <measurement group_id="O3" value="3.29" spread="2.84"/>
                    <measurement group_id="O4" value="4.69" spread="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline and Month 3</title>
        <description>Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline and Month 3</title>
          <description>Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=146, 174, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" spread="3.17"/>
                    <measurement group_id="O2" value="5.61" spread="6.42"/>
                    <measurement group_id="O3" value="5.41" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=138, 148, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="2.85"/>
                    <measurement group_id="O2" value="3.43" spread="2.88"/>
                    <measurement group_id="O3" value="4.57" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 6</title>
        <description>Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.</description>
        <time_frame>Month 6</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 6</title>
          <description>Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="2.85"/>
                    <measurement group_id="O2" value="3.18" spread="3.00"/>
                    <measurement group_id="O3" value="3.21" spread="2.80"/>
                    <measurement group_id="O4" value="3.94" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to First Greater Than 1 Day Sequential Decrease in Pain From Baseline for Patient Assessment of Arthritis Pain</title>
        <description>Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (most severe pain), measurement on a scale corresponds to the magnitude of their pain.</description>
        <time_frame>2 weeks</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Greater Than 1 Day Sequential Decrease in Pain From Baseline for Patient Assessment of Arthritis Pain</title>
          <description>Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (most severe pain), measurement on a scale corresponds to the magnitude of their pain.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to First Greater Than 1 Day Sequential Decrease in Pain From Baseline for Patient Global Assessment of Arthritis</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly.</description>
        <time_frame>2 weeks</time_frame>
        <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Greater Than 1 Day Sequential Decrease in Pain From Baseline for Patient Global Assessment of Arthritis</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly.</description>
          <population>FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3</title>
        <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily up to Month 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3</title>
          <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline:Time management(n=118, 119, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.84" spread="26.52"/>
                    <measurement group_id="O2" value="48.98" spread="27.17"/>
                    <measurement group_id="O3" value="48.74" spread="26.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Physical demands(n=117, 119, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.84" spread="22.44"/>
                    <measurement group_id="O2" value="49.24" spread="27.51"/>
                    <measurement group_id="O3" value="51.21" spread="25.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Mental demands(n=119,120,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.04" spread="24.05"/>
                    <measurement group_id="O2" value="36.14" spread="28.41"/>
                    <measurement group_id="O3" value="38.69" spread="27.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Output demands(n=114, 116, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.70" spread="24.76"/>
                    <measurement group_id="O2" value="44.85" spread="30.23"/>
                    <measurement group_id="O3" value="45.30" spread="28.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Work loss index(n=124, 122, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.82" spread="5.21"/>
                    <measurement group_id="O2" value="11.95" spread="6.20"/>
                    <measurement group_id="O3" value="12.16" spread="5.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Time management(n=94, 89, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.65" spread="29.03"/>
                    <measurement group_id="O2" value="34.63" spread="29.91"/>
                    <measurement group_id="O3" value="41.32" spread="23.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Physical demands(n=98, 90, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.89" spread="29.32"/>
                    <measurement group_id="O2" value="46.48" spread="30.17"/>
                    <measurement group_id="O3" value="46.71" spread="24.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Mental demands(n=100, 93, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.64" spread="27.02"/>
                    <measurement group_id="O2" value="24.62" spread="29.12"/>
                    <measurement group_id="O3" value="28.54" spread="26.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Output demands(n=96, 90, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.03" spread="24.44"/>
                    <measurement group_id="O2" value="28.31" spread="29.37"/>
                    <measurement group_id="O3" value="33.41" spread="23.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3:Work loss index(n=102, 98, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.48" spread="5.60"/>
                    <measurement group_id="O2" value="8.05" spread="6.63"/>
                    <measurement group_id="O3" value="9.29" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Limitations Questionnaire (WLQ) Score at Month 6</title>
        <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).</description>
        <time_frame>Month 6</time_frame>
        <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given parameter for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Limitations Questionnaire (WLQ) Score at Month 6</title>
          <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).</description>
          <population>FAS population. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given parameter for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time management (n=80, 81, 25, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.27" spread="29.22"/>
                    <measurement group_id="O2" value="30.42" spread="28.39"/>
                    <measurement group_id="O3" value="34.40" spread="25.59"/>
                    <measurement group_id="O4" value="39.86" spread="30.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical demands (n=85, 81, 26, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.37" spread="29.86"/>
                    <measurement group_id="O2" value="45.17" spread="34.14"/>
                    <measurement group_id="O3" value="57.16" spread="27.63"/>
                    <measurement group_id="O4" value="50.33" spread="31.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental demands (n= 81, 82, 25, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.66" spread="25.71"/>
                    <measurement group_id="O2" value="21.61" spread="29.09"/>
                    <measurement group_id="O3" value="25.84" spread="24.54"/>
                    <measurement group_id="O4" value="29.77" spread="29.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Output demands (n= 80, 81, 26, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.04" spread="24.29"/>
                    <measurement group_id="O2" value="26.30" spread="29.40"/>
                    <measurement group_id="O3" value="28.65" spread="23.90"/>
                    <measurement group_id="O4" value="35.05" spread="29.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work loss index (n= 85, 85, 26, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.85" spread="5.64"/>
                    <measurement group_id="O2" value="7.60" spread="6.49"/>
                    <measurement group_id="O3" value="9.07" spread="5.22"/>
                    <measurement group_id="O4" value="9.23" spread="6.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP-690550 5 mg (Up To Month 3)</title>
          <description>CP-690550 5 mg tablet orally twice daily up to Month 3.</description>
        </group>
        <group group_id="E2">
          <title>CP-690550 10 mg (Up To Month 3)</title>
          <description>CP-690550 10 mg tablet orally twice daily up to Month 3.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Up To Month 3)</title>
          <description>Matching placebo tablet orally twice daily up to Month 3.</description>
        </group>
        <group group_id="E4">
          <title>CP-690550 5 mg (Post Month 3)</title>
          <description>CP-690550 5 mg tablet orally twice daily from Month 3 to Month 6.</description>
        </group>
        <group group_id="E5">
          <title>CP-690550 10 mg (Post Month 3)</title>
          <description>CP-690550 10 mg tablet orally twice daily from Month 3 to Month 6.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominoplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Breast prosthesis implantation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA v13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="304"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

